MK0653, ezetimibe ( DrugBank: Ezetimibe )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
260	Sitosterolemia	3

260. Sitosterolemia

---

Clinical trials : 12 /  Drugs : 11 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathway : 1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00092898 (ClinicalTrials.gov)	October 2004	23/9/2004	An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia	Lipid Metabolism, Inborn Errors;Heart Disease	Drug: MK0653, ezetimibe;Drug: Comparator: placebo	Organon and Co	NULL	Completed	18 Years	85 Years	All	30	Phase 3	United States
2	NCT00092820 (ClinicalTrials.gov)	February 12, 2001	23/9/2004	Sitosterolemia Extension Study (0653-004)(COMPLETED)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia	Lipid Metabolism, Inborn Errors;Heart Disease	Drug: MK0653, ezetimibe;Drug: Comparator: placebo	Organon and Co	NULL	Completed	10 Years	N/A	All	58	Phase 3	NULL
3	NCT00092807 (ClinicalTrials.gov)	February 12, 2001	23/9/2004	Sitosterolemia Extension Study (0653-003)(COMPLETED)	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension	Lipid Metabolism, Inborn Errors;Heart Disease	Drug: MK0653, ezetimibe;Drug: Comparator: placebo	Organon and Co	NULL	Completed	10 Years	N/A	All	37	Phase 3	United States